Product
lenalidomide
Aliases
Revlimid
8 clinical trials
10 indications
Indication
Multiple MyelomaIndication
Non-Hodgkin lymphomaIndication
Diffuse Large B-Cell LymphomaIndication
Follicular LymphomaIndication
mantle cell lymphomaIndication
Marginal Zone LymphomaIndication
Diffuse Large B-cell LymphomaIndication
lymphomaIndication
Large B-CellIndication
DiffuseClinical trial
A Dose Escalation, Safety, Pharmacokinetic, Pharmacodynamic and Preliminary Efficacy Study of SAR650984 (Isatuximab) Administered Intravenously in Combination With Bortezomib - Based Regimens in Adult Patients With Newly Diagnosed Multiple Myeloma Non Eligible for Transplantation or No Intent for Immediate TransplantationStatus: Completed, Estimated PCD: 2022-01-28
Clinical trial
A Phase Ib, Multi-center, Open-label Dose Escalation and Expansion Platform Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma (NHL)Status: Recruiting, Estimated PCD: 2026-10-30
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone LymphomaStatus: Active (not recruiting), Estimated PCD: 2024-02-23
Clinical trial
A Global Multicenter Phase 1/2 Trial of EO2463, a Novel Microbial-Derived Peptide Therapeutic Vaccine, as Monotherapy, and in Combination With Lenalidomide and Rituximab, for Treatment of Patients With Indolent Non-Hodgkin's LymphomaStatus: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
A Phase 1b/2 Study of Tafasitamab, Tafasitamab Plus Lenalidomide, Tafasitamab Plus Parsaclisib, and Tafasitamab Plus Lenalidomide in Combination With R-CHOP in Japanese Participants With Non-Hodgkin LymphomaStatus: Recruiting, Estimated PCD: 2025-05-31
Clinical trial
Phase 3 Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Compare the Efficacy and Safety of Lenalidomide (CC-5013) Plus R-CHOP Chemotherapy (R2-CHOP) Versus Placebo Plus R-CHOP Chemotherapy in Subjects With Previously Untreated Activated B-cell Type Diffuse Large B-cell LymphomaStatus: Completed, Estimated PCD: 2019-03-15
Clinical trial
A Phase Ib/III Study to Evaluating the Efficacy and Safety of Parsaclisib in Combination With Rituximab and Lenalidomide Versus Rituximab in Combination With Lenalidomide in Subjects With Relapsed or Refractory Follicular LymphomaStatus: Withdrawn, Estimated PCD: 2029-08-31
Clinical trial
A Phase 1b Study of SAR650984 (Anti-CD38 mAb) in Combination With Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple MyelomaStatus: Completed, Estimated PCD: 2023-06-20